Edwards’ Sapien 3 Ultra Valve Wins FDA Approval
Today Edwards Lifesciences Corp. announced that it has received FDA approval for its transcatheter heart valve, the SAPIEN 3 Ultra system. The device features improvements to the valve as well as a new delivery system. The agency approval applies to TAVR in patients who have severe symptomatic aortic stenosis and are at intermediate or greater risk for open heart surgery.
Last year FDA approved expanded use of the Sapien 3 for valve-in-valve treatment, and in January of this year, the company recalled the delivery system for Sapien 3 due to a risk that the overflow material could detach and embolize into the patient.
Related Articles
-
The two new final guidances are intended to increase transparency to stakeholders on the FDA’s approach to the issuance and tracking of 522 orders and post-approval study requirements.
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
